PROCTER & GAMBLE Co executive Paul Gama has filed an initial ownership report showing his equity interests in the company. As CEO – Health Care, he directly holds 35,950.5707 shares of common stock, plus multiple stock options on common shares with exercise prices such as $113.23 and $139.58 expiring between 2030 and 2033. He also holds various Restricted Stock Units that generally settle in P&G common stock or cash under the company’s retirement programs, and additional common and preferred stock are held indirectly through a retirement plan trustee.
The Vanguard Group filed Amendment No. 12 to Schedule 13G/A reporting 0% beneficial ownership of Procter & Gamble Co common stock and an amount beneficially owned of 0 shares. The filing states this follows an internal realignment: certain Vanguard subsidiaries or business divisions will report ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
The filing is a disclosure of ownership structure changes and notes that the disaggregated entities pursue the same investment strategies previously followed by The Vanguard Group, Inc.
PROCTER & GAMBLE Co director Portman Robert Jones reported an amended equity award. The Form 4/A corrects a prior filing that had shown a grant of 193 restricted stock units under the company’s 2025 Stock and Incentive Compensation Plan; the amended report shows an award of 49 RSUs instead. Following this compensation-related acquisition, his directly held common stock position is 5,065.7148 shares, making the change administrative rather than a new trading decision.
Portman Robert Jones reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Robert Jones Portman received an equity award of 193 shares of Common Stock on 2026-03-10.
The award consists of Restricted Stock Units granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, including dividend equivalents in the form of additional units. Following this grant, he holds 5,209.7148 shares directly.
McEvoy Ashley reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Ashley McEvoy received an equity award of 161 shares of Common Stock on 2026-03-10. The transaction is coded as a grant or award, not an open-market purchase, with a price per share of $0.0000, indicating compensation rather than cash investment.
Footnotes explain that the award consists of Restricted Stock Units granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, and that the total includes dividend equivalents in the form of additional Restricted Stock Units. Following this grant, McEvoy directly holds 5,751.065 shares.
McCarthy Christine M reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Christine M. McCarthy received an award of 209 shares of Common Stock on March 10, 2026. The filing describes this as a grant or award transaction, with no cash price per share reported.
These shares are in the form of Restricted Stock Units granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. The total reported direct holdings after this award are 17,128.6365 shares, which include dividend equivalents granted as additional Restricted Stock Units.
Kempczinski Christopher J reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Christopher J. Kempczinski received an award of 201 shares of Common Stock as a grant under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. After this compensation-related award, his directly held stake increased to 11,251.4805 shares, including dividend-equivalent restricted stock units.
JIMENEZ JOSEPH reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Joseph Jimenez received a grant of 273 shares of Common Stock in the form of restricted stock units. The award was made at no cash price as part of The Procter & Gamble 2025 Stock and Incentive Compensation Plan and includes dividend equivalents credited as additional units. After this compensation-related grant, his directly held position reported in this filing increased to 36,512.1482 shares of Common Stock, showing this is a relatively small, routine addition to an existing stake rather than a market purchase or sale.
ARNOLD CRAIG reported acquisition or exercise transactions in this Form 4 filing.
Procter & Gamble director Craig Arnold received a grant of 161 shares of Common Stock through Restricted Stock Units under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. The award, which includes dividend equivalents in the form of additional Restricted Stock Units, increased his directly held position to 2,586.0624 shares.
PROCTER & GAMBLE Co executive Francisco Ma. Fatima, CEO of Baby, Fem & Family Care, reported multiple stock moves. On February 27, 2026, she completed open-market sales totaling 5,549 shares of common stock at prices around $165.29 to $165.32, leaving 1,028.739 directly held shares.
She also received a grant of 57.0033 Restricted Stock Units on February 17, 2026, bringing her direct RSU holdings to 888.7607 units. Footnotes explain these RSUs include dividend equivalents that will deliver in shares at retirement or as deferred compensation. Additional indirect common stock holdings are reported through retirement plans, a spouse, and a SLAT trust.